title: Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model.
abstract: BACKGROUND
  KIOM-CRC#BP3B (BP3B) is a novel herbal prescription that is composed of three plant extracts. Our preliminary study identified that BP3B exhibited potent anti-proliferative activity against various types of cancer cell lines in vitro. Because the in vivo anti-tumor effect of BP3B is not evaluated before clinical trial, we want to test it using patient's samples.
  
  
  METHODS
  To confirm the in vivo anti-cancer effect of BP3B, we used genetically characterized patient-derived colon tumor xenograft (PDTX) mouse model. Anti-cancer activity was evaluated with apoptosis, proliferation, angiogenesis and histological analysis.
  
  
  RESULTS
  Oral administration of BP3B significantly inhibited the tumor growth in two PDTX models. Furthermore, TUNEL assay showed that BP3B induced apoptosis of tumor tissues, which was associated with degradation of PARP and Caspase 8 and activation of Caspase 3. We also observed that BP3B inhibited cancer cell proliferation by down-regulation of Cyclin D1 and induction of p27 proteins. Inhibition of angiogenesis in BP3B-treated group was observed with immunofluorescence staining using CD31 and Tie-2 antibodies.
  
  
  CONCLUSIONS
  These findings indicated that BP3B has a strong growth-inhibitory activity against colon cancer in in vivo model and will be a good therapeutic candidate for treatment of refractory colon cancer.
authors.affiliation: Department of Biochemistry, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, 155 Gaetbel-ro Yeonsu-gu, Incheon, 21999, Republic of Korea.
authors.forename: Hye-Youn
authors.initials: HY
authors.lastname: Kim
authors.affiliation: KM-Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon, 34054, Republic of Korea.
authors.forename: Jinhee
authors.initials: J
authors.lastname: Kim
authors.affiliation: Department of Biochemistry, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, 155 Gaetbel-ro Yeonsu-gu, Incheon, 21999, Republic of Korea.
authors.forename: Huyen Trang
authors.initials: HT
authors.lastname: Ha Thi
authors.affiliation: KM-Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon, 34054, Republic of Korea.
authors.forename: Ok-Sun
authors.initials: OS
authors.lastname: Bang
authors.affiliation: Department of Sugery, Gil Medical Center, Gachon University, Incheon, 21565, Republic of Korea.
authors.forename: Won-Suk
authors.initials: WS
authors.lastname: Lee
authors.affiliation: Department of Biochemistry, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, 155 Gaetbel-ro Yeonsu-gu, Incheon, 21999, Republic of Korea. sthong@gachon.ac.kr.
authors.forename: Suntaek
authors.initials: S
authors.lastname: Hong
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D010936:Plant Extracts / Q000008:administration & dosage*; D010946:Plants, Medicinal / Q000737:chemistry; D023041:Xenograft Model Antitumor Assays
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D010936:Plant Extracts
keywords: BP3B; Colon cancer; Medicinal plant; Patient-derived tumor xenograft